MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from follow-on
public offerings, net...
$147,450K
Proceeds from exercise of
common stock options
$6,456K
Net cash provided by
financing activities
$153,590K
Canceled cashflow
$316K
Net (decrease)
increase in cash and cash...
-$224,578K
Canceled cashflow
$153,590K
Proceeds from sales and
maturities of investments
$844,139K
Stock-based compensation
expense
$26,676K
Accrued expenses and
other current...
$8,655K
Depreciation and
amortization
$1,445K
Non-cash lease expense
$34K
Stock issuance costs
$316K
Net cash used in
investing activities
-$245,822K
Canceled cashflow
$844,139K
Net cash used in
operating activities
-$132,346K
Canceled cashflow
$36,810K
Purchases of investments
$1,067,860K
Acquisition, net of cash
acquired
$21,967K
Purchases of property and
equipment
$134K
Net loss
-$160,995K
Prepaid expenses and
other current assets
$1,900K
Accounts payable
-$1,644K
Other assets
$1,584K
Accretion of discount on
short-term investments
$1,014K
Non-cash interest
expense (income)
$768K
Other liabilities
-$487K
Inventory
$444K
Accounts receivable, net
$320K
Back
Back
Cash Flow
source: myfinsight.com
CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)